564 results about "Glycoprotein" patented technology

The invention relates to the technical field of stem cells, in particular to a lentivirus envelope plasmid combination and application thereof, a lentivirus and a packaging method thereof and a method for transduction of hematopoietic stem cells. The invention provides an envelope plasmid combination for lentivirus packaging, which is composed of lentivirus packaging plasmids containing VSVG glycoprotein and lentivirus packaging plasmids containing BaEV glycoprotein in a ratio of 3: 7. The invention further provides a method for transduction of the hematopoietic stem cells by the lentivirus, the method is simple and convenient to operate, the long-term dryness of the hematopoietic stem cells in vitro can be maintained, efficient and stable transduction of the hematopoietic stem cells can be realized, and the transduction rate is greater than 90%. The lentivirus transduction method hematopoietic stem cells can be used for hematopoietic stem cell gene therapy hematopoietic system genetic diseases, such as severe combined immunodeficiency, beta-thalassemia and sickle cell disease, Wiskott-Aldrich syndrome and the like, and the application prospect is good.

The application discloses a method for recovering active glycoprotein Patatin from potato starch processing waste juice, and belongs to the technical field of protein extraction. The method is characterized in that the active Patatin protein is efficiently separated by using the combination of ammonium sulfate fractionation precipitation, anion exchange chromatography, Con A affinity chromatography and gel chromatography, and the obtained Patatin protein retains the original protein structure and biological function activity. Compared with the prior art, the method has better separation purity and higher efficiency, and the obtained Patatin protein has complete protein higher structure and function activity, and has a better application scene.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

The application belongs to the technical field of biomedical engineering, and particularly relates to a micro-hydrogel wrapping platelets, a freeze-dried powder and a preparation method, use method and application thereof. The micro-hydrogel wrapping platelets, the micro-hydrogel is in a core-shell or multi-chamber structure, and the platelets are wrapped inside; the micro-hydrogel is formed by emulsifying a dispersed phase solution in a continuous phase solution and spontaneously physically gelling, and the platelets are wrapped inside; the micro-hydrogel can reduce the damage to the platelets caused by the freeze-drying process and rehydration, and the platelets can be stored for a long time after freeze-drying; when used, the micro-hydrogel can be dissociated by only rehydrating, centrifuging and heating, without the need of adding an additional decrosslinking agent, and the operation is convenient. The micro-hydrogel wrapping platelets has higher expression of hemostasis-related glycoprotein and lower de-sialylation degree after freeze-drying, rehydration and dissociation, and is expected to have better hemostasis ability and longer in-vivo circulation time; and is expected to greatly extend the storage time of platelets and alleviate the shortage of platelets.

The invention relates to the technical field of detection kits, in particular to a blood coagulation reaction linked lupus anticoagulant fluorescence detection kit and application thereof, the kit contains a screening-confirmation integrated reagent, a calibration product, a quality control product and an anticoagulation interference inhibitor; the integrated reagent is divided into a reagent A and a reagent B, the reagent A contains a buffer solution, recombinant snake venom thrombin, composite phospholipid, a fluorescent substrate and other components, and the reagent B contains prothrombin, calcium ions, high-concentration composite phospholipid and other components; the composite phospholipid system is formed according to a specific proportion and modifies beta2-glycoprotein I, the fluorescence enhancement-stabilization system is formed by matching a Schiff base compound with a stabilizer, the calibrator is a series of lupus anticoagulant standard substances, and the quality control substance comprises simulants with different concentrations and negative control. The anti-interference capability is high, and the influence of anti-coagulant drugs and enzyme source fluctuation is reduced; the signal amplification effect is obvious, the detection sensitivity is high and the reagent stability is good; the operation is simple and convenient, screening and confirmation are integrally completed, and a conventional fluorescence detector is adapted.

Highly potent respiratory syncytial virus (RSV) neutralizing monoclonal antibodies that specifically bind RSV fusion protein (F) or RSV attachment glycoprotein (G) are described. The monoclonal antibodies were synthesized by sequencing RSV G- and RSV F-specific B cells from a human participant of an RSV challenge study. The RSV-specific monoclonal antibodies described herein exhibit potent neutralization of RSV (IC50 as low as 0.4 ng / ml) that is superior to previously disclosed RSV neutralizing antibodies. The RSV-specific monoclonal antibodies can be used, for example, to treat, inhibit and detect RSV infection.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

A varicella-zoster virus (VZV) nanoparticle protein, and a preparation method therefor and a use thereof. The VZV protein comprises a partial or full sequence of an amino acid sequence of an extracellular region of a VZV gE glycoprotein, with W at position 200 mutation to C and L at position 245 mutation to C in the amino acid sequence of the extracellular region of the VZV gE glycoprotein. By means of the rational optimization design of the amino acid sequence of the VZV gE protein by means of protein genetic engineering, the VZV gE recombinant protein modified with amino acid mutations has increased stability and immunogenicity compared with the VZV gE protein. Moreover, by further designing the protein structure, the VZV gE protein is repeatedly displayed on the surface of ferritin nanoparticles with the desired epitopes exposed, thereby further enhancing immunogenicity.

The invention belongs to the technical field of bioengineering and application thereof, and particularly relates to a laver compound zymolyte as well as a preparation method and application thereof. The compound enzyme is prepared through a compound enzymolysis process of protease and laver polysaccharide enzyme. Compared with a traditional single proteolysis process, a composite enzymolysis process of adding the high-enzyme-activity laver polysaccharide enzyme effectively breaks a'polysaccharide-protein 'composite structure of laver cell walls, so that the viscosity of zymolyte is reduced, high laver liquefaction rate and high product yield are realized, and the release efficiency of nutritional active ingredients is remarkably improved; the product is rich in low-molecular-weight polypeptide and oligomeric porphyra polysaccharide. The obtained zymolyte shows the comprehensive effects of improving joint activity, inhibiting osteophyte formation, adjusting cartilage metabolism balance and relieving inflammatory response in an osteoarthritis mouse model, and osteoarthritis is effectively relieved. According to the invention, efficient release and utilization of nutritional active ingredients of the laver are realized, and powerful technical support is provided for developing high-valued products, such as health-care products and functional foods, which have the function of maintaining joint health.

The invention belongs to the field of biological prevention and control, and discloses an insect specific virus NLBV3 and application thereof in reducing transmission of rice odontodwarf virus of brown planthopper. The NLBV3 virus genome comprises three chains, the L chain encodes RNA dependent RNA polymerase (RdRP), the M chain encodes glycoprotein precursor (GP), the S chain encodes nucleoprotein (NP), and the nucleotide sequences are respectively shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; the application is realized by releasing the NLBV3-carrying brown planthopper population, and according to the screening and detection method of the NLBV3-carrying brown planthopper high-virus population provided by the invention, natural brown planthoppers can be effectively infected after the NLBV3-carrying brown planthopper high-virus population is released, the RRSV transmission capability of the brown planthoppers is reduced, and the virus is prevented from damaging rice production. The NLBV3 provided by the invention is an insect specific virus, is harmless to mammals, fishes and shrimps, natural enemy insects and pollination insects, and has the advantages of specific action object, environment friendliness and the like.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

Described are modified Varicella Zoster Virus glycoprotein E (VZV gE) proteins having improved stability and / or immunogenicity compared to a non-modified VZV gE. Also described are associated nucleic acids, immunogenic compositions, and methods of using such modified VZV gE proteins in the treatment or prevention of shingles.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present disclosure relates to polypeptides comprising an antigen fragment of the receptor binding domain (RBD) of coronavirus spike glycoprotein, protein nanostructures thereof, methods of manufacture thereof, and prophylactic and therapeutic uses thereof. In various aspects, the antigen fragment comprises a coronavirus subdomain 1 (SD1).

The present invention involves an engineered probiotic bacterium comprising a heterologous nucleic acid, where the heterologous nucleic acid comprises a nucleic acid sequence encoding an anti-spike glycoprotein nanobody of a coronavirus. In one embodiment, the bacterium is Escherichia coli Nissle 1917. In another embodiment, the anti-spike glycoprotein nanobody appears on the surface of the probiotic bacteria.

The present invention discloses a fluorescent probe and its preparation method and application. The structural formula of the fluorescent probe of the present invention is: ‑ Cl ‑ Br ‑ , I ‑ The fluorescent probe of the present invention can rapidly undergo a bioorthogonal shear reaction to specifically activate fluorescence at the tumor site, thereby improving the imaging specificity of the target site. Simultaneously, the bioorthogonal coupling group of the probe is used to undergo biocoupling with cells, allowing the probe to be anchored on tumor cell membrane glycoproteins for long-term fluorescence imaging. The probe is suitable for non-invasive detection of tumors and surgical resection of tumors.

The invention belongs to the technical field of biological medicine, and provides an antibody targeting Gn glycoprotein on the surface of a severe fever with thrombocytopenia syndrome virus and application of the antibody. The antibodies N2C1 and N2D2 and the bispecific antibody obtained by modification based on the antibodies N2C1 and N2D2 provided by the invention can be specifically combined with Gn glycoprotein on the surface of the severe fever with thrombocytopenia syndrome virus, and show a strong neutralization protection effect in in-vitro cell and in-vivo animal experiments. Therefore, the N2C1 and N2D2 antibodies and the bispecific antibody obtained by modification can be used as drugs for preventing or treating severe fever with thrombocytopenia syndrome virus infection.

This invention relates to the field of biotechnology, specifically to a composition containing a multivalent pneumococcal polysaccharide-protein conjugate for the prevention of pneumococcal infection and VZV infection, its preparation method, and its application. The composition of this invention, comprising a multivalent pneumococcal polysaccharide-protein conjugate, uses an immunogenic VZV recombinant protein as the carrier protein; the pneumococcal polysaccharide is covalently linked to the VZV recombinant protein; the VZV recombinant protein is selected from gE protein, and its amino acid sequence is shown in SEQ ID NO: 3 or SEQ ID NO: 4. This invention addresses the prevalence of serotypes of pneumococcus unique to my country by creatively selecting serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. This results in a composition containing polyvalent pneumococcal polysaccharide-protein conjugates designed specifically for the prevalence of these serotypes in my country.

The application discloses a Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ and a preparation method thereof, and particularly relates to the technical field of nano-enzymes. The Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ is a cluster-shaped nanoparticle obtained by treating a product separated and purified from Sinonovacula constricta under ultrahigh pressure, and the particle size distribution is 30-50 nm. The preparation method comprises the following steps: taking soft body tissue of Sinonovacula constricta, homogenizing and defatting, centrifuging to collect the precipitate to obtain defatted powder, extracting the defatted powder by an alkali extraction and alcohol precipitation method, adjusting the pH to 4.0-5.0, collecting and drying the precipitate to obtain a crude glycoprotein; subjecting the crude glycoprotein to enzymolysis, and then sequentially subjecting the glycoprotein to anion exchange chromatography and gel filtration chromatography to collect an active component to obtain a Sinonovacula constricta natural glycoprotein; adding deionized water or a phosphate buffer to the Sinonovacula constricta natural glycoprotein to prepare a solution, and placing the solution in an ultrahigh pressure device to obtain the Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ. The Sinonovacula constricta glycoprotein nano-enzyme Sc-NZ has the advantages of being prepared by green physical modification, high activity, high stability and multifunction.

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

The present disclosure provides immunogenic and vaccine compositions comprising a Varicella Zoster Virus (VZV) glycoprotein E (gE) antigen comprising SEQ ID NO: 2 and an SLA adjuvant for use in the prevention of herpes zoster.

The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.

This invention relates to the field of biomedical technology, providing the application of glycoprotein tumor biomarkers in the preparation of cancer diagnostic reagents. The glycoprotein tumor biomarker is a CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification. This invention utilizes CLU_N_291_HexNAc(4)Hex(5) site-specific glycosylation modification as a pan-cancer biomarker, combining it with existing conventional tumor markers (CEA, CA19-9, CA50, CA242, CA72-4, CA125, CA15-3, AFP, SCC, CYFRA21-1, PROGRP, NSE, HE-4, or PSA) for early cancer screening, assessment, diagnosis, postoperative monitoring, and / or prognostic analysis, particularly for the diagnosis of pancreatic cancer, cholangiocarcinoma, gastric cancer, lung cancer, breast cancer, or ovarian cancer.

The disclosure provides a chimeric antigen receptor (CAR) polypeptide having an antigen binding domain comprising an extracellular lectin which specifically binds to glycoproteins expressed on the surface of target cells. Also provided herein are engineered lymphocytes expressing the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods of treating cancer.

The invention relates to the technical field of biological medicine, in particular to mussel mucin and hyaluronic acid cross-linked self-repairing eye health care cream and a 4D forming method thereof. The composition comprises stearic acid, cetostearyl alcohol and the like, a lactic acid bacteria fermentation extract, a jasmine flower extract, a wolfberry extract, a pseudo-ginseng extract, a cassia seed extract, a polygonum cuspidatum extract, a chrysanthemum extract, a leontopodium leontopodum extract, ethylparaben, methylparaben and the like, decapeptide-4, mussel mucin, proteoglycan protein and modified graphene. Modified graphene in the self-repairing eye health care cream can effectively promote crosslinking of mussel mucin and hyaluronic acid and improve the repairing effect, the micro-current effect of graphene can also promote skin tissue to absorb traditional Chinese medicine components and deeply repair eyes, the effect can be more obvious according to personal eye conditions and requirements, and the self-repairing eye health care cream has a good application prospect. The composition has the effects of relieving asthenopia, dryness and soreness, effectively delaying excessive growth of an ocular axis, relieving temporary myopia drift, relieving asthenopia and protecting near vision.

Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.